Q3 2026 Harvard Bioscience, Inc. Earnings Conference Call - HARVARD BIOSCIENCE INC

Explicit Guidance:

• Full Year 2026 Revenue: Reaffirmed growth guidance of 3% to 5%.
• Full Year 2026 Adjusted Gross Margin: Maintained target range of 57% to 59%.
• Full Year 2026 Adjusted EBITDA: Lowered growth guidance from 6–10% to a range of negative 1% to 4%.
• Q4 2026 Revenue: Guidance set between $23.7 million and $25.5 million (midpoint $24.6 million), representing mid-single-digit year-over-year growth.
• Q4 2026 Adjusted Gross Margin: Projected between 59% and 61%.
• Q4 2026 Adjusted EBITDA: Expected between $3.8 million and $4.2 million, representing 5% growth at the midpoint.
• 2027 EBITDA Growth: Anticipated EBITDA growth in Q4 2026 to the midpoint, with expectations of 60% gross margin in 2027 following manufacturing consolidation.

Business-Segment Outlook:

• Organoids & Fluidics: Double-digit momentum in organoid and fluidics products continues; organoid-related products attributed to over 11% of total revenue, with management prioritizing expansion of this New Product Innovation (NPI) contribution.
• Telemetry: Expected to remain a steady growth driver, currently up mid-single digits year-to-date, driven by in vivo safety and efficacy monitoring demand.
• Respiratory & Inhalation: Continued double-digit growth in preclinical respiratory and inhalation products; strong year-to-date CRO sales.
• China Operations: Revenue grew 31% in Q3; all three localized BTX electroporation product lines are now fully available; further product line localization planned for 2027 to drive revenue and margin improvement.
• Distribution Channels: Fisher Scientific North America sales have more than doubled year-to-date; distribution sales to CROs in APAC are a primary growth engine.
• Academic Sector: Currently challenging (down 5% in Europe due to weak academic environment); represents ~40% of direct business; management views modest future recovery as a potential upside tailwind.
• Preclinical Drug Pipelines: Industry forecasts project a 7% increase in clinical trial starts over coming years due to the 2030 patent cliff, supporting demand for preclinical platforms.

Market and Competitive Outlook:

• Market Share: Management acknowledges strong global growth but states it is difficult to quantify specific market share gains against competitors like Thermo, Lonza, and MaxSight.
• Bioproduction Strategy: BTX bioproduction version (GMP approval) expected to be fully launched by mid-year 2027, expanding beyond the current research-focused market.
• Pricing & Mix: Current mix includes higher sales of lower-margin legacy products and distribution channels (particularly in China), temporarily depressing gross margins until Project Viking is complete.
• Structural Shifts: Industry trend toward "new approach methodologies" (NAMs) and human-relevant data generation aligns with company's organoid technology adoption.

Macro / Industry Outlook:

• Economic Environment: Academic funding environments in the U.S. and Europe have been slower to recover than anticipated; Europe specifically saw negative growth.
• Political/Regulatory: Potential upside for NIH and academic spending if Democrats control Congress, though current guidance does not assume this benefit.
• Currency: European revenue was 3% lower on a constant currency basis in Q3, indicating FX impact or underlying demand weakness.
• Interest Rates: Higher interest costs on debt contributed to Q3 operational cash flow changes; debt facility matures December 2029.

Strategic Initiatives:

• Project Viking (Manufacturing Consolidation): On target for completion in Q1 2027; currently completed relocation of amino acid analyzer to UK and begun parallel build of Fluidics in Minneapolis.
• Cost Savings from Viking: Expected to generate $3 million in cost savings in 2027 and $4 million annually thereafter, contributing directly to adjusted EBITDA.
• Commercial Realignment: New dedicated key accounts group established to manage top-tier pharma, CRO, and biotech customers; revamped commercial team delivering encouraging results.
• Scientific Advisory Board: Established to guide technology roadmap; will hold quarterly meetings.
• Debt Refinancing: Exploring conversion of $10 million term loan B to an asset-based revolver to secure interest savings and working capital flexibility; progress made with potential announcement pending.
• Inventory Management: Inventory increased by ~$3 million to support manufacturing pre-builds for Project Viking; expected to drop significantly once transition concludes in Q1 2027, aiding cash generation.

Risks and Headwinds to Outlook:

• Product Mix Headwinds: Greater-than-expected demand for lower-margin legacy products and increased sales through distribution channels (including lower-margin China sales) negatively impact gross margin and EBITDA growth for the full year.
• Academic Funding Volatility: Continued softness in the European academic environment and potential instability in U.S./EU NIH funding could impact revenue.
• Execution Risks: Project Viking transition must complete by Q1 2027 to realize projected cost savings and cash flow improvements; delays could impact 2027 financial targets.
• Debt Structure: Amortization of debt does not commence until late December 2027; unamortized deferred financing costs and exit fee accruals impact current earnings.
• Competitive Landscape: Competition from larger players (Thermo, Lonza) is stronger in the bioproduction sector, limiting BTX market penetration in that area prior to 2027 launch.

Management Tone on the Future:

• Confidence Level: High confidence in the business trajectory for 2027, citing "solid top-line performance," "healthy demand," and operational milestones "firmly on schedule."
• Caveats: Acknowledged that current EBITDA guidance is lower due to temporary product mix shifts, but expressed belief that "meaningful benefits to our bottom line" will follow the completion of manufacturing consolidation.
• Sustainability: Viewed Q2 and Q3 growth as a "return to sales growth that is believed to be sustainable," driven by CRO demand and distribution expansion rather than one-off orders.

Miscellaneous:

• Non-GAAP Measures: Adjusted EBITDA and Gross Margin are used to evaluate performance, excluding stock comp, amortization, depreciation, and restructuring charges (except for Project Viking transition costs).
• Cash Position: Ended quarter with $4.9 million in cash and cash equivalents; net debt of $35.1 million (up ~$7.6 million YoY).
• Reverse Split: All per-share numbers retroactively reflect the 1-for-10 reverse stock split completed in March 2026.